Atlas Trials

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases

Clinical trial NCT05807893 · COMPLETED

Trial details

NCT number
NCT05807893
Sponsor
Sun Yat-sen University
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer Stage IIBevacizumabImmunotherapyBrain Metastases
Start date
2023-05-14
Primary completion
2024-03-22
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.